医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

MetLife Creates “360Health” – Insurance Solutions Focused on Increasing Healthspan

2019年04月11日 PM01:08
このエントリーをはてなブックマークに追加


 

HONG KONG

Insights gathered from close to 30,000 consumers across markets in Asia reveal that as many as 60 percent of people would rather live a shorter healthy life, than a longer life with a serious illness like cancer, dementia or heart disease1.

Customers surveyed in China, Japan, Korea and Australia also reveal that people are worried about the burden serious illness would bring upon their family, yet less than half believe they’re doing enough or are confident they know how to prevent it.

MetLife has created 360Health, an end-to-end health solution in Asia to directly address these concerns and help customers increase their “healthspan” (the number of healthy years in their overall lifespan) by preventing and managing serious illness.

“After listening deeply to our customers, we designed a solution that goes beyond products towards an integrated offering that combines insurance products with health services to deliver a simple and engaging customer experience,” said Kishore Ponnavolu, President of MetLife Asia.

MetLife already holds a number of leading market positions in Asia and is the first insurer to create a dedicated regional brand for its health solutions portfolio focused on helping customers prevent and manage serious illnesses through a number of first-in-market solutions.

“Part of our job as protectors and partners to help people navigate the twists and turns of life is to provide solutions that help them prevent, diagnose and manage serious health conditions so they can enjoy longer healthspans, as well as lifespans,” said Ponnavolu.

MetLife launched its 360Health solution in South Korea this week, where customers and their family members will now have access to market-leading health protection products in addition to a wide selection of innovative health services, like discounted genetic testing for cancer and pharmacogenomic testing, as well as a private nurse to accompany and support patients attending medical appointments for a critical illness 2.

MetLife customers in China were first to experience 360Health in 2018 with the launch of three signature solutions, that include services like overseas health checks and real-time co-diagnosis between doctors in China and the United States. A fourth solution, “Safeguarding Your Health Plus”, launched this week, giving customers access to flexible combinations of coverage to address their personal health protection needs at different life stages.

MetLife plans to expand 360Health to additional markets over time and will continue to roll out new and innovative solutions to meet the evolving needs of people in Asia.

About MetLife

MetLife, Inc. (NYSE: MET), through its subsidiaries and affiliates (“MetLife”), is one of the world’s leading financial services companies, providing insurance, annuities, employee benefits and asset management to help its individual and institutional customers navigate their changing world. Founded in 1868, MetLife has operations in more than 40 countries and holds leading market positions in the United States, Japan, Latin America, Asia, Europe and the Middle East. For more information, visit www.metlife.com.

1 Source: Healthspan Quantitative Research, June-July 2018

2 Total face amount of the products they own must exceed USD44,000

View source version on businesswire.com: https://www.businesswire.com/news/home/20190410005955/en/

CONTACT

Yvette Marmur, MetLife Asia: M. +852 5716 8533 | E. ymarmur@metlife.com

同じカテゴリーの記事 

  • Kolmar BNH, a Top-Tier Korean Enterprise Specializing in the Production of HemoHIM, Dedicates over 2% of its Annual Sales to R&D
  • Takeda公布2023财年全年业绩和2024财年展望,确认对后期研发管线开发和提高核心营业利润率的承诺
  • Shionogi & Co., Ltd. and Maze Therapeutics, Inc. Announce Exclusive Worldwide License Agreement for MZE001, a Novel Therapeutic Candidate for the Treatment of Pompe Disease
  • AMLにおける寛解期に残存するFLT3-ITD変異と移植後の転帰との間に重要な関連があることが研究によって判明
  • 研究表明AML缓解期残留FLT3-ITD突变与移植后结果之间存在重要联系